WO1999065887A1 - Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents - Google Patents

Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents Download PDF

Info

Publication number
WO1999065887A1
WO1999065887A1 PCT/US1999/013397 US9913397W WO9965887A1 WO 1999065887 A1 WO1999065887 A1 WO 1999065887A1 US 9913397 W US9913397 W US 9913397W WO 9965887 A1 WO9965887 A1 WO 9965887A1
Authority
WO
WIPO (PCT)
Prior art keywords
selected
group consisting
alkyl
yl
ethyl
Prior art date
Application number
PCT/US1999/013397
Other languages
French (fr)
Inventor
Wayne Everett Childers
Michael Gerard Kelly
Yvette Latko Palmer
Edward James Podlesny
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US9746398A priority Critical
Priority to US09/097,463 priority
Application filed by American Home Products Corporation filed Critical American Home Products Corporation
Publication of WO1999065887A1 publication Critical patent/WO1999065887A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18Ethylenedioxybenzenes, not substituted on the hetero ring

Abstract

This invention relates to compounds which have activity as 5-HT1A agonists and antagonists which may be useful for the treatment of anxiety, depression, cognitive deficits, and prostate cancer. Useful compounds are those of formula (I) where: X is selected from the group consisting of (1), (2), (3); n is selected from the integers 1 through 5; R1 is optionally substituted C¿6?-C10-aryl or mono or bicyclic heteroaryl, with a proviso that heteroaryl is not thiadiazole; R?2¿ is selected from the group consisting of H and C¿1?-C6 alkyl; R?3¿ is selected from the group consisting of H, COR?5, COOR5¿, and CONR?5R6; R4, R5 and R6¿ are as defined hereinabove; or an optical isomer; or a pharmaceutically acceptable salt thereof.

Description

CYCLOALKYL-SUBSTITUTED ARYL-PIPERAZINES, PIPERIDINES AND TETRAHYDROPYRIDINES AS SEROTONERGIC AGENTS

Background of the Invention

Compounds having selective partial agonist activity at the 5-HTIA receptor have established a presence in the marketplace as effective anxiolytic agents (buspirone, Buspar®, US Patent 3,717,634). 5-HTIA agonists and antagonists may find use in the treatment of several diseases such as anxiety, depression, schizophrenia, cognitive deficits resulting from neurodegenerative diseases like Alzheimer's Disease, nausea and vomiting, and in the treatment of prostate cancer (for recent references, see: K. Rasmussen and V. P. Rocco, Recent Progress in Serotonin (5-HT)jA Receptor Modulators, in Annual Reports in Medicinal Chemistry, Volume 30, J. A. Bristol, ed., pp. 1-9 (1995)).

Description of the Invention

In accordance with this invention, there is provided a set of novel compounds, including their enantiomers, which have activity as 5-HTi A agonists and antagonists. Compounds of the present invention are described by the generic formula:

Figure imgf000003_0001
where: X is selected from the group consisting of:
Figure imgf000003_0002

n is selected from the integers 1 through 5;

R1 is C6-Cιo-aryl or mono or bicyclic heteroaryl, optionally substituted by F, Cl, Br, I, -OH, -NH2, CO2H, -CO2-Cι-C6 alkyl, -CN, -NO2, - alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cι-C6 perhaloalkyl, OR4, and -CO perhaloalkoxy, with a proviso that heteroaryl is not thiadiazole; R2 is selected from the group consisting of H and Cι-C6 alkyl;

R3 is selected from the group consisting of H, COR5, COOR5, and CONR5R6;

R4 is selected from the group consisting of H, Cι-C6 alkyl, C2-C alkenyl, C2-C6 alkynyl, C6-Cιo aryl, mono or bicyclic heteroaryl, C -Ci4 aralkyl, and mono or bicyclic heteroaralkyl, where the aryl or heteroaryl group is optionally substituted with one to three substituents independently selected from the group consisting of F, Cl, Br, I, CN, -NH2, -NO2, -OH, alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cι-C6 perhaloalkyl, Cι-C6 alkoxy, and Cι-C6 perhaloalkoxy;

R5 and R6 are selected independently from the group consisting of H, Cι-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C2-C6 cycloalkenyl, adamantyl, and noradamantyl or R5 and R6 taken together with the interposed nitrogen atom may form a 5-7 membered azacyclic ring, optionally containing an additional heteroatom selected from O, S, or NR4; the optical isomers; and the pharmaceutically acceptable salts thereof.

The term C6-Cιo aryl includes phenyl and naphthyl. Monocyclic heteroaryl means a 5-6 membered heteroaryl group having from 1-3 heteroatoms selected independently from N, O, and S, such as pyridine, pyrrole, thiophene, furan, imidazole, oxazole, pyrimidine, pyridazine, pyrazine, thiazole and oxathiazole. Bicyclic heteroaryl includes phenyl fused to a monocyclic 5-6 membered heteroaryl group or a 5-6 membered heteroaryl group fused to another 5-6 membered heteroaryl group, including, but not limited to indole, quinoline, isoquinoline, benzofuran, benzodioxan, benzothiophene, benzimidazole, naphthyridine, and imidazopyridine. The term C -Ci4 aralkyl means a C1-C4 alkyl group having a phenyl or naphthyl group as a substituent, and the term heteroaralkyl means a C1-C4 alkyl group having a mono or bicyclic heteroaryl group as defined above as a substituent.

Optical isomers of the invention compounds can be selectively synthesized or separated using conventional procedures known to those skilled in the art of organic synthesis.

The pharmaceutically acceptable salts of the invention compounds include the conventional acid addition salts which are formed from an invention compound and a pharmaceutically acceptable organic or inorganic acid. The acid addition salts include, but is not limited to, the acetate, adipate, alginate, aspartate, benzoate, benzene- sulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, dodecylsulfate, ethanesulfonate, fumarate, glycerophosphate, phosphate, hemisulfate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, methanesulfonate, nicotinate, oxalate, pamoate, pectinate, pivalate, propionate, succinate, tartrate, and tosylate. Also the basic nitrogen-containing groups may be quatemized with such agents as lower alkyl halides, dialkyl sulfates, long chain halides such as lauryl bromide, aralkyl halides like benzyl and phenethyl bromides.

Detailed Description of the Invention

Compounds in which at least one of R2 and R3 is hydrogen are synthesized in four steps (Scheme 1) starting from cycloalkylalanine which has been protected on the nitrogen atom with the t-butoxycarbonyl group (BOC). This material is coupled to the appropriately substituted aryl heterocycle where X is CH, N, or carbon having a double bond to an adjacent carbon atom using dicyclohexylcarbodiimide (DCC) to afford compound 1. Removal of the BOC group under acidic conditions followed by reduction using a borane complex leads to the penultimate intermediate 2. Subsequent acylation of 2 with the appropriate acid chloride gives compound 3, which is isolated as an acceptable salt.

Scheme 1.

Figure imgf000005_0001

2

Compounds in which both R2 and R3 are other than hydrogen are prepared using two general methods. Reduction of BOC-protected amide 1 with lithium aluminum hydride (LAH) affords methylamine 4 in one step (Scheme 2). Subsequent acylation using the appropriate acid chloride yields N-methylamide 5. Scheme 2.

Figure imgf000006_0001

Alternatively, acylation of intermediate 2 followed by reduction with an appropriate reduction agent such as borane*dimethylsulfide gives alkylamine 6, which can then be converted to the final acylated product 7 (Scheme 3).

Scheme 3.

Figure imgf000006_0002

2 6

Figure imgf000006_0003

7

Carbamates and ureas can be prepared from the intermediate amines 2, 4, and 6 either by treatment with an appropriate isocyanate or by reacting the amine with a phosgene equivalent such as trichloromethylchloroformate or triphosgene followed by treatment with an appropriate alcohol or amine. Other synthetic procedures may be apparent to those skilled in the art of organic synthesis. The compounds of this invention are prepared by conventional methods which are well known to one skilled in the art of chemistry using chemicals that are either commercially available or readily prepared following standard literature procedures.

The following examples are included for illustrative purposes only and are not intended to be considered as limiting to this disclosure in any way.

Example 1

Cyclohexanecarboxylic acid {(lR)-l-cyclohexylmethyl-2-[4-(2- methoxyphenyl)-piperazin-l-yI]-ethyI}-amide To a solution of 0.31 g (0.94 mmol) of {(lR)-l-cyclohexylmethyl-2-[4-(2- methoxyphenyl)-piperazin-l-yl]-ethyl} -amine and 0.26 mL (1.87 mmol) of triethylamine in 10 mL of dichloromethane at 0°C was added dropwise 0.15 g (1.03 mmol) of cyclohexanecarboxylic acid chloride in 4 mL of dichloromethane. The reaction mixture was allowed to stir under nitrogen at 0°C for one hour, and was then concentrated on a rotary evaporator, diluted with ethyl acetate and washed with saturated aqueous NaHCO3 and brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (dichloromethane/methanol) and then converted to the dihydrochloride salt of the title compound with ethanolic HCl to yield 0.41 g (85%) as a beige solid; mp = 121-131°C;

MS (+) ESI m/z = 442 (M+H)+.

Analysis for C27H43N3O2 • 2HC1

Calculated: C: 63.02; H: 8.81; N: 8.17

Found: C: 63.56; H: 9.27; N: 8.07.

Example 2

1-Methyl-cyclohexanecarboxylic acid {(lR)-l-cyclohexylmethyl-2-[4-(2- methoxyphenyl)-piperazin-l-yl]-ethyl}-amide

To a solution of 0.30 g (0.91 mmol) of {(lR)-l-cyclohexylmethyl-2-[4-(2- methoxyphenyl)-piperazin-l-yl] -ethyl} -amine and 0.25 mL (1.74 mmol) of triethylamine in 10 mL of dichloromethane at 0°C was added dropwise 0.16 g (1.00 mmol) of 1-methyl-cyclohexanecarboxylic acid chloride in 4 mL of dichloromethane.

The reaction mixture was allowed to stir under nitrogen at 0°C for one hour, and was then concentrated on a rotary evaporator, diluted with ethyl acetate and washed with saturated aqueous NaHCO3 and brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (dichloromethane/methanol) and then converted to the hydrochloride • hydrate salt of the title compound with ethanolic HCl to yield 0.30 g (63%) of a light yellow solid; mp = 119-121°C; MS (+) ESI m/z = 456 (M+H)+. Analysis for C28H45N3O2 • HCl • H2O Calculated: C: 65.92; H: 9.48; N: 8.24 Found: C: 65.85; H: 9.26; N: 7.67.

Example 3

Cyclohexanecarboxylic acid {(lR)-l-cycIohexylmethyl-2-[4-(2- methoxyphenyl)-piperazin-l-yl]-ethyl}-methyl-amide

To a solution of 0.30 g (0.87 mmol) of {(lR)-l-cyclohexylmethyl-2-[4-(2- methoxyphenyl)-piperazin-l-yl]-ethyl}-methyl-amine and 0.25 mL (1.74 mmol) of triethylamine in 10 mL of dichloromethane at 0°C was added dropwise 0.19 g (1.31 mmol) of cyclohexanecarboxylic acid chloride in 4 mL of dichloromethane. The reaction mixture was allowed to stir under nitrogen overnight at ambient temperature, and was then concentrated on a rotary evaporator, diluted with ethyl acetate and washed with saturated aqueous NaHCO3 and brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (dichloromethane/methanol) and then converted to the dihydrochloride salt with ethanolic HCl to yield 0.41 g (89%) of the title compound as a white solid; mp = 222-

224°C; MS (+) ESI m/z = 456 (M+H)+. Analysis for C27H43N3O2 • 2HC1

Calculated: C: 63.62; H: 8.96; N: 7.95 Found: C: 63.11; H: 8.81; N: 7.97.

Example 4 1-Methyl-cyclohexanecarboxylic acid {(lR)-l-cyclohexylmethyl-2-[4-(2- methoxyphenyl)-piperazin-l-yl]-ethyl}-methyl-amide

To a solution of 0.30 g (0.87 mmol) of {(lR)-l-cyclohexylmethyl-2-[4-(2- methoxyphenyl)-piperazin-l-yl]-ethyl}-methyl-amine and 0.25 mL (1.74 mmol) of triethylamine in 10 mL of dichloromethane at 0°C was added dropwise 0.21 g (1.31 mmol) of 1-methyl-cyclohexanecarboxylic acid chloride in 4 mL of dichloromethane. The reaction mixture was allowed to stir under nitrogen overnight at ambient temperature, and was then concentrated on a rotary evaporator, diluted with ethyl acetate and washed with aqueous NaHCO3 and brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (dichloromethane/methanol) and then converted to the dihydrochloride salt of the title compound with ethanolic HCl to yield 0.41 g (86%) of white solid; mp = 208-210°C;

MS (+) ESI m/z = 470 (M+H)+ Analysis for C29H47N3O2 • 2HC1 Calculated: C: 64.19; H: 9.10; N: 7.74 Found: C: 63.89; H: 9.03; N: 7.93.

Example 5 Cyclohexanecarboxylic acid {(lR)-l-cyclohexylmethyl-2-[4-(2,3)- dihydrobenzo[l,4]-dioxin-5-yl)-piperazin-l-yl]-ethyl}-methyl-amide

To a solution of 0.7 g (1.87 mmol) of {(lR)-l-cyclohexylmethyl-2-[4-(2,3-dihydro- benzo[l,4]dioxin-5-yl)-piperazin-l-yl]-ethyl}-methyl-amine and 0.5 mL (3.7 mmol) of triethylamine in 10 mL of dichloromethane at 0°C was added dropwise 0.27 g (1.87 mmol) of cyclohexanecarboxylic acid chloride in dichloromethane. The reaction mixture was allowed to stir under nitrogen overnight at ambient temperature, and was then concentrated on a rotary evaporator, diluted with ethyl acetate and washed with H2O and brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (ethyl acetate/hexanes) and then converted to the hydrochloride • hemihydrate salt of the title compound with ethereal HCl to yield 0.82 g

(91%) as a white solid; mp = 147-148°C; MS (+) ESI m/z = 484 (M+H)+. Analysis for C29H45N3O3 • HCl • 0.5 H2O Calculated: C: 65.82; H: 8.95; N: 7.94 Found: C: 65.90; H: 9.04; N: 7.98.

Example 6 l-Methyl-cyclohexanecarboxylic acid {(lR)-l-cyclohexylmethyl-2-[4-

(2,3-dihydro-benzo[l,4]dioxin-5-yl)-piperazin-l-yl]ethyl}-methylamide

To a solution of 0.7 g (1.87 mmol) of {(lR)-l-cyclohexylmethyl-2-[4-(2,3-dihydro- benzo[l,4]dioxin-5-yl)-piperazin-l-yl]-ethyl}-methyl-amine and 0.5 mL (3.7 mmol) of triethylamine in 10 mL of dichloromethane at 0°C was added dropwise 0.3 g (1.87 mmol) of 1-methyl-cyclohexanecarboxylic acid chloride in dichloromethane. The reaction mixture was allowed to stir under nitrogen overnight at ambient temperature and was then concentrated on a rotary evaporator, diluted with ethyl acetate and washed with H2O and brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (ethyl acetate/hexanes) and converted to the hydrochloride salt of the title compound with ethereal HCl to yield 0.85 g (91%) of the title compound as a white solid; mp = 219-220°C; MS (+) ESI m/z = 498 (M+H)+. Analysis for C3oH47N3O3 • HCl

Calculated: C: 67.45; H: 9.06; N: 7.87 Found: C: 67.04; H: 9.17; N: 7.88.

Example 7 Cyclohexanecarboxylic acid {(lR)-l-cyclohexylmethyl-2-[4-(lH-indol-

4-yl)-piperazin-l-yI]-ethyl}-methyl-amide

To a solution of 0.6 g (1.69 mmol) of {(lR)-l-cyclohexylmethyl-2-[4-(lH-indol-4-yl)- piperazin-l-yl]-ethyl}-methyl-amine and 0.5 mL (3.7 mmol) of triethylamine in 10 mL of dichloromethane at 0°C was added dropwise 0.25 g (1.69 mmol) of cyclohexanecarboxylic acid chloride in dichloromethane. The reaction mixture was allowed to stir under nitrogen overnight at ambient temperature, and was then concentrated on a rotary evaporator, diluted with ethyl acetate and washed with H2O and brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (ethyl acetate/hexanes) and converted to the hydrochloride • 0.3 hydrate salt of the title compound with ethereal HCl yield 0.68 g

(87%) as a white solid; mp = >260°C; MS (+) ESI m/z = 465 (M+H)+. Analysis for C29H44N4O • HCl • 0.3 H2O Calculated: C: 68.76; H: 9.07; N: 11.06 Found: C: 68.52; H: 9.15; N: 11.18. Example 8 l-Methyl-cyclohexanecarboxylic acid {(lR)-l-cyclohexylmethyl-2-[4-(l- indol-4-yl)-piperazin-l-yl]-ethyI}-methyl-amide

To a solution of 0.6 g (1.69 mmol) of {(lR)-l-cyclohexylmethyl-2-[4-(lH-indol-4-yl)- piperazin-l-yl]-ethyl}-methyl-amine and 0.5 mL (3.7 mmol) of triethylamine in 10 mL of dichloromethane at 0°C was added dropwise 0.27 g (1.69 mmol) of 1-methyl- cyclohexanecarboxylic acid chloride in dichloromethane. The reaction mixture was allowed to stir under nitrogen overnight at ambient temperature and was then concentrated on a rotary evaporator, diluted with ethyl acetate and washed with H2O and brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (ethyl acetate/hexanes) and converted to the hydrochloride salt of the title compound with ethereal HCl to yield 0.7 g (87%) as a white solid; mp = 253-254°C; MS (+) ESI m/z = 479 (M+H)+ Analysis for Analysis for C30H46N4O • HCl Calculated: C: 69.94; H: 9.20; N: 10.88 Found: C: 69.68; H: 9.21; N: 10.89.

Example 9 N-{(lR)-l-cyclohexyImethyl-2-[4-(2-methoxyphenyl)- piperazin-l-yl]ethyI}-formamide

A mixture of 2.10 mL (23.6 mmol) of glacial acetic acid and 1.23 mL (32.1 mmol) of formic acid was stirred at 60°C for 4 hours to form the mixed anhydride. The resulting solution was added slowly to an ice-cooled solution of 1.18 g (3.56 mmol) of {(1R)-1- cyclohexylmethyl-2-[4-(2-methoxyphenyl)-piperazin-l-yl]-ethyl}-amine in 35 mL of anhydrous tetrahydrofuran under nitrogen. The reaction mixture was stirred under nitrogen overnight at ambient temperature and was then poured slowly into 60 mL of saturated aqueous NaHCO3 and stirred for 10 minutes. The layers were separated and the aqueous phase was extracted with two additional portions of ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (dichloromethane/methanol) and converted to the hydrochloride • 1.5 hydrate salt of the title compound with ethanolic HCl to yield 1.03 g (80%) of white solid; mp = 157-159°C; MS (+) ESI m/z = 360 (M+H)+. Analysis for C21H33N3O2 • HCl • 1.5 H2O Calculated: C: 59.62; H: 8.81; N: 9.93 Found: C: 59.54; H: 8.63; N: 9.33.

Example 10

Cyclohexanecarboxylic acid {(lR)-l-cyclohexylmethyl-2-[4-(2- methoxyphenyl)-piperidin-l-yl]-ethyl}-amide

To a solution of 0.076 g of potassium carbonate (0.54 mmol) in 1 ml. of water was added a solution of 0.18 g of {(lR)-l-cyclohexylmethyl-2-[4-(2-methoxyphenyl)- piperidin-l-yl]-ethyl} -amine (0.54 mmol) in 10 mL of dichloromethane. The resulting mixture was cooled to 0°C and 0.076 mL of cyclohexanecarboxylic acid chloride (0.54 mmol) was added. The reaction was allowed to stir overnight at 0°C, and was then diluted with 5 mL of water and 20 mL of dichloromethane and the phases separated. The aqueous phase was extracted with three additional portions of dichloromethane. The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (dichloromethane/methanol) and converted to the hydrochloride • hydrate salt of the title compound with isopropanolic HCl to yield

0.177 g (68%) of white solid; mp = 100-103° C; MS (+) ESI m/z = 441 (M+H)+. Analysis for C28H44N2O2 • HCl • H2O Calculated: C: 67.91; H: 9.56; N: 5.66 Found: C: 68.15; H: 9.57; N: 5.59.

Example 11 1-Methyl-cyclohexanecarboxylic acid {(lR)-l-cyclohexylmethyl-2-[4-(2- methoxyphenyl)-piperidin-l-yl]-ethyl}-amide

To a solution of 0.076 g of potassium carbonate (0.54 mmol) in 1 ml. of water was added a solution of 0.18 g of {(lR)-l-cyclohexylmethyl-2-[4-(2-methoxyphenyl)- piperidin-l-yl]-ethyl} -amine (0.54 mmol) in 10 mL of dichloromethane. The resulting mixture was cooled to 0°C and 0.085 g of 1-methyl-cyclohexanecarbonyl chloride (0.54 mmol) was added. The reaction was allowed to stir overnight at 0°C, and was then diluted with 5 mL of water and 20 mL of dichloromethane and the phases separated. The aqueous phase was extracted with three additional portions of dichloromethane, and the combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (dichloromethane/methanol) and converted to the hydrochloride • 0.75 hydrate salt of the title compound with isopropanolic HCl to yield 0.35 g (55%) as a white solid; mp = 208-210° C; MS (+)

ESI m/z = 455 (M+H)+. Analysis for C28H44N2O2 • HCl • 0.75 H2O Calculated: C: 69.01; H: 9.69; N: 5.55 Found: C: 69.03; H: 9.60; N: 5.45.

Example 12 Cyclohexanecarboxylic acid {(lR)-l-cyclohexylmethyl-2-[4-(2- methoxyphenyl)-piperidin-l-yl]-ethyl}-methyl-amide

To a solution of 0.080 g of potassium carbonate (0.58 mmol) in 1 ml. of water was added a solution of 0.20 g of {(lR)-l-cyclohexylmethyl-2-[4-(2-methoxyphenyl)- piperidin-l-yl]-ethyl}-methyl-amine (0.58 mmol) in 10 mL of dichloromethane. The resulting mixture was cooled to 0°C and 0.090 g of cyclohexanecarboxylic acid chloride (0.58 mmol) was added. The reaction was allowed to stir overnight at 0°C, and was then diluted with 5 mL of water and 20 mL of dichloromethane and the phases separated. The aqueous phase was extracted with three additional portions of dichloromethane. The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (dichloromethane/methanol) and converted to the hydrochloride • 0.75 hydrate salt of the title compound with isopropanolic HCl to yield 0.195 g (69%) as a white solid; mp = 135-137° C; MS (+)

ESI m/z = 455 (M+H)+. Analysis for C29H46N2O2 • HCl • 0.75 H2O Calculated: C: 69.01; H: 9.69; N: 5.55 Found: C: 69.07; H: 9.52; N: 5.19.

Example 13 1-Methyl-cyclohexanecarboxylic acid {(lR)-l-cyclohexylmethyl-2-[4-(2- methoxyphenyl)-piperidin-l-yl]-ethyl}-methyl-amide

To a solution of 0.08 g of potassium carbonate (0.58 mmol) in 1 ml. of water was added a solution of 0.18 g of {(lR)-l-cyclohexylmethyl-2-[4-(2-methoxyphenyl)- piperidin-l-yl]-ethyl}-methyl-amine (0.58 mmol) in 10 mL of dichloromethane. The resulting mixture was cooled to 0°C and 0.093 g of 1-methyl-cyclohexanecarboxylic acid chloride (0.58 mmol) was added. The reaction was allowed to stir overnight at 0°C, and was then diluted with 5 mL of water and 20 mL of dichloromethane and the phases separated. The aqueous phase was extracted with three additional portions of dichloromethane, and the combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (dichloromethane/methanol) and converted to the hydrochloride • 0.75 hydrate salt of the title compound with isopropanolic HCl to yield 0.220 g (75%) of white solid; mp = 169-171° C; MS (+)

ESI m/z = 469 (M+H)+ Analysis for C30H48N2O2 • HCl • 0.75 H2O Calculated: C: 69.52; H: 9.82; N: 5.40 Found: C: 69.44; H: 9.61; N: 4.94.

Example 14 N-{(lR)-l-cyclohexylmethyI-2-[4-(2-methoxyphenyl)-piperidin-l-yl]- ethyl}-2,2-dimethyl-propionamide

To a solution of 0.076 g of potassium carbonate (0.54 mmol) in 1 ml. of water was added a solution of 0.18 g of {(lR)-l-cyclohexylmethyl-2-[4-(2-methoxyphenyl)- piperidin-1-yl] -ethyl} -amine (0.54 mmol) in 10 mL of dichloromethane. The resulting mixture was cooled to 0°C and 0.066 g of trimethylacetyl chloride (0.54 mmol) was added. The reaction was allowed to stir overnight at 0°C, and was then diluted with 5 mL of water and 20 mL of dichloromethane and the phases separated. The aqueous phase was extracted with three additional portions of dichloromethane. The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (dichloromethane/methanol) and converted to the hydrochloride • 0.75 hydrate salt of the title compound with isopropanolic HCl to yield

0.137 g (56%) of white solid; mp = 97-99° C; MS (+) ESI m/z = 415 (M+H)+ Analysis for C26H42N2O2 • HCl • 0.75 H2O Calculated: C: 67.22; H: 9.65; N: 6.02 Found: C: 66.91; H: 9.68; N: 5.90. Example 15

N-{(lR)-l-cyclohexylmethyI-2-[4-(2-methoxyphenyl)-piperidin-l-yl]- ethyl}-2,2,N-trimethyl-propionamide

To a solution of 0.08 g of potassium carbonate (0.58 mmol) in 1 ml. of water was added a solution of 0.20 g of {(lR)-l-cyclohexylmethyl-2-[4-(2-methoxyphenyl)- piperidin-l-yl]-ethyl}-methyl-amine (0.58 mmol) in 10 mL of dichloromethane. The resulting mixture was cooled to 0°C and 0.075 g of trimethylacetyl chloride (0.62 mmol) was added. The reaction was allowed to stir overnight at 0°C, and was then diluted with 5 mL of water and 20 mL of dichloromethane and the phases separated. The aqueous phase was extracted with three additional portions of dichloromethane. The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (dichloromethane/methanol) and converted to the hydrochloride • 0.25 hydrate salt of the title compound with isopropanolic HCl to yield 0.157 g (58%) of white solid; mp = 233-236° C; MS (+) ESI m/z = 429 (M+H)+. Analysis for C27H44N2O2 • HCl • 0.25 H2O Calculated: C: 69.05; H: 9.77; N: 5.97 Found: C: 69.28; H: 9.96; N: 5.90.

Example 16

1-Methyl-cyclohexanecarboxylic acid {(lR)-l-cyclohexylmethyl-2-[4-(2- methoxyphenyl)-3,6-dihydro-2H-pyridin-l-yl]-ethyl}-amide

To a solution of 0.25 g (0.76 mmol) of {(lR)-l-cyclohexylmethyl-2-[4-(2- methoxyphenyl)-3,6-dihydro-2H-pyridin-l-yl]-ethyl} -amine and 0.21 mL (1.52 mmol) of triethylamine in 10 mL of dichloromethane at 0°C was added dropwise 0.13 g (0.84 mmol) of 1-methyl-cyclohexanecarboxylic acid chloride in 4 mL of dichloromethane. The reaction mixture was allowed to stir under nitrogen at 0°C for one hour, and was then concentrated on a rotary evaporator, diluted with ethyl acetate and washed with saturated aqueous NaHCO3 and brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (dichloromethane/- methanol) and then converted to the hydrochloride • hemihydrate salt of the title compound with ethanolic HCl to yield 0.15 g (41%) of yellow solid; mp = 93-95°C;

MS (+) ESI m/z = 453 (M+H)+. Analysis for C29H44N2O2 • HCl • 0.5 H2O Calculated: C: 69.92; H: 9.31; N: 5.62 Found: C: 69.92; H: 9.03; N: 5.23.

PHARMACOLOGY

Affinity for the serotonin 5-HTIA receptor was established by assaying the test compound's ability to displace [3H] 8-OHDPAT from its binding site on the receptor complex in CHO cells stably transfected with the human 5-HTIA receptor following the procedure described by J. Dunlop, Y. Zhang, D. Smith and L. Schechter (Eur. J. Pharmacol., submitted; variation of a procedure described by J. Zgombick et al., Naunyn-Schmiedeberg's Arch. Pharmacol., 354, 226-236 (1996)). The compounds of this invention displayed high affinity for the 5-HTIA receptor, as described in Table 1.

Table 1

5-HT1A Affinity Agonist Activity Antagonist Activity

Example (IC50) GTPγS (EC50) cAMP (IC50)

Example 1 0.57 nM 0.9 nM -

Example 2 1.23 nM - 14.6 nM

Example 3 1.46 nM - 4.0 nM

Example 4 2.82 nM - 10.2 nM

Example 5 2.37 nM - 4.6 nM

Example 6 6.92 nM - 7.3 nM

Example 7 8.84 nM - 10.5 nM

Example 8 32.68 nM - -

Example 9 1.49 nM - 17.3 nM

Example 10 1.08 nM 3.9 nM -

Example 11 5.97 nM - 46.0 nM

Example 12 1.69 nM - 91.5 nM

Example 13 5.33 nM - 97.5 nM

Example 14 2.19 nM - 40.0 nM

Example 15 5.00 nM - -

Example 16 2.75 nM - 45.5 nM Some of the compounds of this invention displayed 5-HTΪA partial agonist activity, as assessed by the test compound's ability to stimulate the binding of [35S]-GTPγS to the 5-HTIA receptor-G protein complex in CHO cells stably transfected with the human 5- HTΪA receptor following a variation of the procedure described by Lazareno and Birdsall [Br. J. Pharmacol., 109, 1120 (1993)]. Selected compounds of this invention which demonstrated agonist activity in this assay are shown in Table 1.

Some of the compounds of this invention demonstrated 5-HTΪA antagonist activity, as measured by the test compound's ability to inhibit forskolin-stimulated cAMP turnover in CHO cells stably transfected with the human 5-HTIA receptor using a procedure described by J. Dunlop, Y. Zhang, D. Smith and L. Schechter [Eur. J. Pharmacol., submitted; variation of a procedure described by J. Zgombick et al., Naunyn-Schmiedeberg's Arch. Pharmacol., 354, 226-236 (1996)]. Selected compounds of this invention which demonstrated 5-HTIA antagonist activity in this are shown in Table 1.

PHARMACEUTICAL COMPOSITION Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or encapsulating materials. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.

Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs. The active ingredient in this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g. cellulose derivatives, preferable sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form.

Preferably the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.

The dosage to be used in the treatment of a specific disease must be subjectively determined by the attending physician. The variables involved include the specific disease state and the size, age and response pattern of the patient.

Claims

WE CLA :
1. A compound according to the formula
Figure imgf000019_0001
where:
X is selected from the group consisting of:
Figure imgf000019_0002
n is selected from the integers 1 through 5;
R1 is Ce- o-aryl or mono or bicychc heteroaryl having 5-10 atoms, 1 to 3 of which are heteroatoms selected independently from N, S or O, wherein the aryl or heteroaryl group is optionally substituted by F, Cl, Br, I, -OH, -NH2, CO2H, -CO2-C╬╣-C6 alkyl, -CN, -NO2, C╬╣-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -C6 perhaloalkyl, OR4, and C╬╣-C6 perhaloalkoxy, with a proviso that heteroaryl is not thiadiazole; R2 is selected from the group consisting of H and -C6 alkyl; R3 is selected from the group consisting of H, COR5, COOR5, and CONR5R6; R4 is selected from the group consisting of H, -C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C╬╣o aryl or mono or bicychc heteroaryl as defined above, C7-Ci4 aralkyl, and mono or bicychc heteroaralkyl, where the aryl or mono or bicyclic heteroaryl group is as defined above and optionally substituted with one to three substituents independently selected from the group consisting of F, Cl, Br, I, CN, -NH2, -NO2, -OH, alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -C6 perhaloalkyl, Cj-C6 alkoxy, and C]-C6 perhaloalkoxy;
R5 and R6 are selected independently from the group consisting of H, C╬╣-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C2-C6 cycloalkenyl, adamantyl, and noradamantyl or R5 and R6 taken together with the interposed nitrogen atom may form a 5-7 membered azacyclic ring, optionally containing an additional heteroatom selected from O, S, or NR4; or an optical isomer; or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 having the formula
Figure imgf000020_0001
where:
X is selected from the group consisting of:
FlHsj N- - R1ΓÇö N- -
Figure imgf000020_0002
n is selected from the integers 1 through 5; R1 is Cό- o-aryl or mono or bicyclic heteroaryl, optionally substituted by F, Cl, Br, I, CO2H, -CO2-Cι-C6 alkyl, -CN, -NO2, -Q- alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C--C6 perhaloalkyl, OR4, and -C6 perhaloalkoxy, with a proviso that heteroaryl is not thiadiazole; R2 is selected from the group consisting of H and Cι-C6 alkyl; R3 is selected from the group consisting of H, COR5, COOR5, and CONR5R6;
R4 is selected from the group consisting of H, Cι-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cό-Cio aryl, mono or bicychc heteroaryl, C -C!4 aralkyl, and mono or bicychc heteroaralkyl, where the aryl or heteroaryl group is optionally substituted with one to three substituents independently selected from the group consisting of F, Cl, Br, I, CN, -NO2, Cι-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cι-C6 perhaloalkyl, Cι-C6 alkoxy, and -C6 perhaloalkoxy; R5 and R6 are selected independently from the group consisting of H, C]-C6 alkyl,
C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C2-C6 cycloalkenyl, adamantyl, and noradamantyl or R5 and R6 taken together with the interposed nitrogen atom forms piperidine, morpholine, or piperazine substituted at the 4 position by a substituent selected from R4; or an optical isomer; or a pharmaceutically acceptable salt thereof.
3. A compound according to claim 1 which is:
cyclohexanecarboxylic acid { ( 1 R)- 1 -cyclohexylmethyl-2- [4-(2-methoxyphenyl)- piperazin- 1 -yl]-ethyl } -amide,
1-methyl-cyclohexanecarboxylic acid { (IR)- l-cyclohexylmethyl-2-[4-(2-methoxy- phenyl)-piperazin- 1 -yl]-ethyl } -amide,
cyclohexanecarboxylic acid { ( 1 R)- 1 -cyclohexylmethyl-2- [4-(2-methoxyphenyl)- piperazin- 1 -yl]-ethyl } -methyl-amide,
1 -methyl-cyclohexanecarboxylic acid { ( 1 R)- 1 -cyclohexylmethyl-2- [4-(2-methoxy- phenyl)-piperazin- 1 -yl]-ethyl } -methyl-amide,
cyclohexanecarboxylic acid { ( IR)- 1 -cyclohexylmethyl-2-[4-(2,3)-dihydrobenzo[ 1 ,4]- dioxin-5-yl)-piperazin- 1 -yl]-ethyl } -methyl-amide,
1 -methyl-cyclohexanecarboxylic acid { ( 1 R)- 1 -cyclohexylmethyl-2-[4-(2,3-dihydro- benzo[ 1 ,4]dioxin-5-yl)-piperazin- 1 -yl]ethyl } -methyl-amide,
cyclohexanecarboxylic acid { ( 1 R)- 1 -cyclohexylmethyl-2- [4-( 1 H-indol-4-yl)-piperazin- 1 -yl]-ethyl } -methyl-amide,
1 -methyl-cyclohexanecarboxylic acid { ( 1 R)- 1 -cyclohexylmethyl-2- [4-) 1 -indol-4-yl)- piperazin- 1 -yl]-ethyl } -methyl-amide,
N- { ( 1 R)- 1 -cyclohexylmethyl-2- [4-(2-methoxyphenyl)-piperazin- 1 -yl]ethyl } - formamide,
cyclohexanecarboxylic acid {(lR)-l-cyclohexylmethyl-2-[4-(2-methoxyphenyl)- piperidin- 1 -yl] -ethyl } -amide,
1-methyl-cyclohexanecarboxylic acid { ( IR)- 1 -cyclohexylmethyl-2- [4-(2- methoxyphenyl)-piperidin- 1 -yl]-ethyl } -amide, cyclohexanecarboxylic acid { ( 1 R)- 1 -cyclohexylmethyl-2- [4-(2-methoxyphenyl)- piperidin- 1 -y 1] -ethyl } -methyl-amide,
1 -methyl-cyclohexanecarboxylic acid { ( 1 R)- 1 -cyclohexylmethyl-2- [4-(2- methoxyphenyl)-piperidin- 1 -yl]-ethyl } -methyl-amide,
N- { ( 1 R)- 1 -cyclohexylmethyl-2- [4-(2-methoxyphenyl)-piperidin- 1 -y 1] -ethyl } -2,2- dimethyl-propionamide,
N- { ( 1 R)- 1 -cyclohexylmethyl-2-[4-(2-methoxyphenyl)-ρiperidin- 1 -yl]-ethyl } -2,2,N- trimethyl-propionamide, or
1 -methyl-cyclohexanecarboxylic acid { ( 1 R)- 1 -cyclohexylmethyl-2- [4-(2- methoxyphenyl)-3 ,6-dihydro-2H-pyridin- 1 -yl]-ethyl } -amide,
or an optical isomer thereof, or a pharmaceutically acceptable salt thereof.
4. A method of treating conditions in mammals modulated by serotonin 5-HT╬╣ A receptors in the central nervous system and in the body which comprises administration to a mammal having such a condition a therapeutically effective amount of a compound according to the formula
T X/IChyn
R- 3 where:
X is selected from the group consisting of:
Figure imgf000022_0001
RL CH RUΛ-__H n is selected from the integers 1 through 5; R1 is C6-Cιo-aryl or mono or bicychc heteroaryl having 5-10 atoms, 1 to 3 of which are heteroatoms selected independently from N, S or O, wherein the aryl or heteroaryl group is optionally substituted by F, Cl, Br, I, -OH, -NH2, CQ2H,
-CO2-C1-C6 alkyl, -CN, -NO2, C╬╣-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cj-Cg perhaloalkyl, OR4, and C╬╣-C6 perhaloalkoxy, with a proviso that heteroaryl is not thiadiazole;
R2 is selected from the group consisting of H and C╬╣-C6 alkyl;
R3 is selected from the group consisting of H, COR5, COOR5, and CONR5R6; R4 is selected from the group consisting of H, Cj-C╬▓ alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C╬╣o aryl or mono or bicychc heteroaryl as defined above, C7-C14 aralkyl, and mono or bicychc heteroaralkyl, where the aryl or mono or bicychc heteroaryl group is as defined above and optionally substituted with one to three substituents independently selected from the group consisting of F, Cl, Br, I, CN, -NH2, -NO2, -OH, alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C╬╣-C6 perhaloalkyl, Cj-C6 alkoxy, and -C6 perhaloalkoxy;
R5 and R6 are selected independently from the group consisting of H, C--C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C2-C6 cycloalkenyl, adamantyl, and noradamantyl or R5 and R6 taken together with the interposed nitrogen atom may form a 5-7 membered azacyclic ring, optionally containing an additional heteroatom selected from O, S, or NR4; or an optical isomer; or a pharmaceutically acceptable salt thereof.
5. The method according to claim 4 wherein the condition treated is depression.
6. The method according to claim 4 wherein the condition treated is anxiety.
7. The method according to claim 4 wherein the condition treated is impaired memory and/or learning resulting from neurodegenerative diseases such as Alzheimer's disease.
8. The method according to claim 4 wherein the condition treated is prostate cancer.
9. The method according to claim 4 wherein the condition treated is nausea and vomiting.
10. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the formula
Figure imgf000024_0001
where:
X is selected from the group consisting of:
Figure imgf000024_0002
n is selected from the integers 1 through 5; R1 is C6-C╬╣o-aryl or mono or bicychc heteroaryl having 5-10 atoms, 1 to 3 of which are heteroatoms selected independently from N, S or O, wherein the aryl or heteroaryl group is optionally substituted by F, Cl, Br, I, -OH, -NH2, CO2H, -CO2-C╬╣-C6 alkyl, -CN, -NO2, C╬╣-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cj-C6 perhaloalkyl, OR4, and C╬╣-C6 perhaloalkoxy, with a proviso that heteroaryl is not thiadiazole;
R2 is selected from the group consisting of H and - alkyl; R3 is selected from the group consisting of H, COR5, COOR5, and CONR5R6; R4 is selected from the group consisting of H,
Figure imgf000024_0003
alkyl, C2-C6 alkenyl, C2- alkynyl, Cβ-Cio aryl or mono or bicychc heteroaryl as defined above, C7-Cj4 aralkyl, and mono or bicychc heteroaralkyl, where the aryl or mono or bicyclic heteroaryl group is as defined above and optionally substituted with one to three substituents independently selected from the group consisting of F, Cl, Br, I, CN, -NH2, -NO2, -OH, alkyl, C -C6 alkenyl, C2-C6 alkynyl, Cι-C6 perhaloalkyl, Cι-C6 alkoxy, and Cι-C6 perhaloalkoxy; R5 and R6 are selected independently from the group consisting of H, Cj-Cό alkyl, C2-C6 alkenyl, C2-C alkynyl, C3-C6 cycloalkyl, C2-C6 cycloalkenyl, adamantyl, and noradamantyl or R5 and R6 taken together with the interposed nitrogen atom may form a 5-7 membered azacyclic ring, optionally containing an additional heteroatom selected from O, S, or NR4; or an optical isomer; or a pharmaceutically acceptable salt thereof.
PCT/US1999/013397 1998-06-15 1999-06-14 Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents WO1999065887A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US9746398A true 1998-06-15 1998-06-15
US09/097,463 1998-06-15

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
BR9911280-9A BR9911280A (en) 1998-06-15 1999-06-14 Aryl piperazines, piperidines and tetrahydro pyridines with alkyl as serotonergic agents cycle
EP19990928648 EP1087954A1 (en) 1998-06-15 1999-06-14 Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
CA 2334254 CA2334254A1 (en) 1998-06-15 1999-06-14 Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
AU45663/99A AU4566399A (en) 1998-06-15 1999-06-14 Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
JP2000554713A JP2002518382A (en) 1998-06-15 1999-06-14 Cycloalkyl as serotonin agonists - substituted aryl - piperazine, piperidine and tetrahydropyridine

Publications (1)

Publication Number Publication Date
WO1999065887A1 true WO1999065887A1 (en) 1999-12-23

Family

ID=22263490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013397 WO1999065887A1 (en) 1998-06-15 1999-06-14 Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents

Country Status (7)

Country Link
EP (1) EP1087954A1 (en)
JP (1) JP2002518382A (en)
CN (1) CN1312802A (en)
AU (1) AU4566399A (en)
BR (1) BR9911280A (en)
CA (1) CA2334254A1 (en)
WO (1) WO1999065887A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376494B1 (en) * 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
WO2002085871A2 (en) * 2001-04-04 2002-10-31 Wyeth Serotonergic agents with long-acting in vivo effects
US7067518B2 (en) 2002-09-05 2006-06-27 Wyeth Pyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0395313A2 (en) * 1989-04-22 1990-10-31 American Home Products Corporation Tertiary alkyl functionalized piperazine derivatives
EP0434561A2 (en) * 1989-12-20 1991-06-26 Adir Et Compagnie 1-Naphthyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them
EP0506468A1 (en) * 1991-03-29 1992-09-30 Eli Lilly And Company N-substituted 4-phenyl-piperidine opioid-antagonists
EP0512755A2 (en) * 1991-05-02 1992-11-11 JOHN WYETH & BROTHER LIMITED Piperazine derivatives
WO1993003016A1 (en) * 1991-07-30 1993-02-18 Boehringer Ingelheim Italia S.P.A. Benzimidazolone derivatives as 5-ht1a and 5-ht2 antagonists
WO1993011122A1 (en) * 1991-12-05 1993-06-10 John Wyeth & Brother Limited Piperazine derivatives as 5-ht1a antagonists
WO1994021610A1 (en) * 1993-03-24 1994-09-29 John Wyeth & Brother Limited Piperazine derivatives as 5-ht1a ligands
WO1995033743A1 (en) * 1994-06-03 1995-12-14 John Wyeth & Brother Limited Piperazine derivatives as 5ht1a antagonists
WO1995033729A1 (en) * 1994-06-08 1995-12-14 H. Lundbeck A/S Serotonin 5-ht1a and dopamin d2 receptor ligands
WO1996001656A1 (en) * 1994-07-08 1996-01-25 John Wyeth & Brother Limited 5-ht1a ligands
WO1996016949A1 (en) * 1994-12-02 1996-06-06 Pierre Fabre Medicament Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs
EP0737678A1 (en) * 1995-04-10 1996-10-16 American Home Products Corporation 4-Indolylpiperazinyl derivatives
WO1997040038A1 (en) * 1996-04-18 1997-10-30 Merck Patent Gmbh Piperidines and pyrrolidines

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0395313A2 (en) * 1989-04-22 1990-10-31 American Home Products Corporation Tertiary alkyl functionalized piperazine derivatives
EP0434561A2 (en) * 1989-12-20 1991-06-26 Adir Et Compagnie 1-Naphthyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them
EP0506468A1 (en) * 1991-03-29 1992-09-30 Eli Lilly And Company N-substituted 4-phenyl-piperidine opioid-antagonists
EP0512755A2 (en) * 1991-05-02 1992-11-11 JOHN WYETH & BROTHER LIMITED Piperazine derivatives
WO1993003016A1 (en) * 1991-07-30 1993-02-18 Boehringer Ingelheim Italia S.P.A. Benzimidazolone derivatives as 5-ht1a and 5-ht2 antagonists
WO1993011122A1 (en) * 1991-12-05 1993-06-10 John Wyeth & Brother Limited Piperazine derivatives as 5-ht1a antagonists
WO1994021610A1 (en) * 1993-03-24 1994-09-29 John Wyeth & Brother Limited Piperazine derivatives as 5-ht1a ligands
WO1995033743A1 (en) * 1994-06-03 1995-12-14 John Wyeth & Brother Limited Piperazine derivatives as 5ht1a antagonists
WO1995033729A1 (en) * 1994-06-08 1995-12-14 H. Lundbeck A/S Serotonin 5-ht1a and dopamin d2 receptor ligands
WO1996001656A1 (en) * 1994-07-08 1996-01-25 John Wyeth & Brother Limited 5-ht1a ligands
WO1996016949A1 (en) * 1994-12-02 1996-06-06 Pierre Fabre Medicament Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs
EP0737678A1 (en) * 1995-04-10 1996-10-16 American Home Products Corporation 4-Indolylpiperazinyl derivatives
WO1997040038A1 (en) * 1996-04-18 1997-10-30 Merck Patent Gmbh Piperidines and pyrrolidines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
D.L. NELSON, PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR, vol. 40, 1991, pages 1041 - 1051, XP002114414 *
GLENNON R A ET AL: "N-(PHTHALIMIDOALKYL) DERIVATIVES OF SEROTONERGIC AGENTS: A COMMON INTERACTION AT 5-HT1A SEROTONIN BINDING SITES?", JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 8, 1 August 1989 (1989-08-01), pages 1921 - 1926, XP000571455, ISSN: 0022-2623 *
GLENNON R A ET AL: "STIMULUS PROPERTIES OF ARYLPIPERAZINES: NAN-190, A POTENTIAL 5 -HT1A SEROTONIN ANTAGONIST", DRUG DEVELOPMENT RESEARCH, vol. 16, no. 2/04, 1 January 1989 (1989-01-01), pages 335 - 343, XP000575594, ISSN: 0272-4391 *
GLENNON R A: "CONCEPTS FOR THE DESIGN OF 5-HT1A SEROTONIN AGONISTS AND ANTAGONISTS", DRUG DEVELOPMENT RESEARCH, vol. 26, no. 3, 1 January 1992 (1992-01-01), pages 251 - 274, XP000562325, ISSN: 0272-4391 *
I.A. CLIFFE ET AL., DRUGS OF THE FUTURE, vol. 18, no. 7, 1993, pages 631 - 642, XP002114577 *
SLEIGHT A J ET AL: "IDENTIFICATION OF 5-HYDROXYTRYPTAMINE1A RECEPTOR AGENTS USING A COMPOSITE PHARMACOPHORE ANALYSIS AND CHEMICAL DATABASE SCREENING", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 343, 1 January 1991 (1991-01-01), pages 109 - 116, XP000650292 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376494B1 (en) * 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6518272B2 (en) * 1998-06-15 2003-02-11 Wyeth Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US7049330B2 (en) 1998-06-15 2006-05-23 Wyeth Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
WO2002085871A2 (en) * 2001-04-04 2002-10-31 Wyeth Serotonergic agents with long-acting in vivo effects
WO2002085871A3 (en) * 2001-04-04 2003-02-20 Wyeth Corp Serotonergic agents with long-acting in vivo effects
US6696450B2 (en) 2001-04-04 2004-02-24 Wyeth Serotonergic agents with long-acting in vivo effects
US6894053B2 (en) 2001-04-04 2005-05-17 Wyeth Serotonergic agents with long-acting in vivo effects
US7067518B2 (en) 2002-09-05 2006-06-27 Wyeth Pyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
WO2011076708A1 (en) 2009-12-22 2011-06-30 Peter Gmeiner New aminotetraline derivatives
US8586603B2 (en) 2009-12-22 2013-11-19 Peter Gmeiner Aminotetraline derivatives
US8691839B2 (en) 2009-12-22 2014-04-08 Peter Gmeiner Aminotetraline derivatives

Also Published As

Publication number Publication date
CA2334254A1 (en) 1999-12-23
CN1312802A (en) 2001-09-12
JP2002518382A (en) 2002-06-25
EP1087954A1 (en) 2001-04-04
AU4566399A (en) 2000-01-05
BR9911280A (en) 2001-03-13

Similar Documents

Publication Publication Date Title
DE60125335T2 (en) Azacyclic compounds for use in the treatment of related diseases with serotonin
KR0128210B1 (en) 1-indolyalkyl-4-(substituted-pyridinyl) piperazines
JP2785879B2 (en) Therapeutically useful 2-aminotetralin derivatives
JP3955614B2 (en) Phenyl as serotonin reuptake inhibitors - piperazine derivative
AU658475B2 (en) New azaindoles preparation processes and medicinal products containing them
JP2845341B2 (en) N- (3- hydroxy-4-piperidinyl) (dihydrobenzofuran, dihydro -2h- benzopyran or dihydro-benzodioxin) carboxamide derivatives
RU2070884C1 (en) Derivatives of n-(4-piperidinyl)-(dihydrobenzofuran or dihydro-2h-benzopyran)-carboxamide or their salts, or their stereoisomers, methods of their synthesis, intermediate compounds for their, pharmaceutical composition based on derivatives of n-(4-piperidinyl)-(dihydrobenzofuran or dihydro-2h-benzopyran)-carboxamide
AU2004268840B9 (en) Benzimidazolone compounds having 5-HT4 receptor agonistic activity
US3853915A (en) 9-or 10-halo-4h-benzo{8 4,5{9 cyclo-hepta{8 1,2-b{9 thiophen-4-ones
US6498168B2 (en) Muscarinic antagonists
RU2193561C2 (en) Derivatives of piperazine, method of their synthesis, pharmaceutical composition, intermediate compound
AU701420B2 (en) Novel piperazides derived from arylpiperazine, processes for their preparation, their use as medicaments and pharmaceutical compositions comprising them
US7326722B2 (en) N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy
EP1221443B1 (en) Substituted imidazolidinone derivatives
US6140344A (en) 4-aroylpiperidine derivatives-CCR-3 receptor antagonists
US7205319B2 (en) N-[phenyl (piperidin-2-yl) methyl]benzamide derivatives, preparation thereof, and use thereof in therapy
AU650182B2 (en) Novel azaheterocyclylmethyl-chromans
CN1118452C (en) 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, its producing process medicinal composition containing the same compound and intermediate of the compound
KR100413150B1 (en) Dihydrobenzodioxine carboxamide and ketone derivatives as 5-ht4 receptor antagonists
CA2124680C (en) Piperazine derivatives as 5-ht1a antagonists
RU2095360C1 (en) Indole derivatives, their optical isomers and pharmaceutically acceptable salts
JP2957476B2 (en) Indole derivatives
CA2554642C (en) Bicyclic carbonyl amino derivatives as chemokine receptor antagonists
CA2059708C (en) Indole derivatives
EP0277794B1 (en) N-heterocyclic-N-(4-piperidyl) amides

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99809567.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1999928648

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2334254

Country of ref document: CA

ENP Entry into the national phase in:

Ref document number: 2000 554713

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/012479

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1999928648

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999928648

Country of ref document: EP